Buy Rating on Cormedix Affirmed Amidst DefenCath's Strong Market Entry and Growth Prospects
JMP Securities Maintains CorMedix(CRMD.US) With Buy Rating, Maintains Target Price $19
Rodman & Renshaw Initiates CorMedix(CRMD.US) With Buy Rating, Announces Target Price $13
Cormedix Analyst Ratings
Truist Financial Maintains CorMedix(CRMD.US) With Buy Rating
A Quick Look at Today's Ratings for CorMedix(CRMD.US), With a Forecast Between $9 to $19
Cormedix (CRMD) Gets a Buy From Truist Financial
Cormedix Analyst Ratings
Needham Reiterates Buy on Cormedix, Maintains $10 Price Target
Truist Securities Maintains Buy on Cormedix, Lowers Price Target to $12
Cormedix Analyst Ratings
Truist Financial Maintains CorMedix(CRMD.US) With Buy Rating, Cuts Target Price to $12
Cormedix Analyst Ratings
Cormedix Analyst Ratings
Analysts' Opinions Are Mixed on These Healthcare Stocks: Beam Therapeutics (BEAM), Cormedix (CRMD) and Applied Therapeutics (APLT)
Analysts' Top Healthcare Picks: Cormedix (CRMD), SCYNEXIS (SCYX)
Truist Financial Reaffirms Their Buy Rating on Cormedix (CRMD)
Analysts Offer Insights on Healthcare Companies: Altimmune (ALT), Evolent Health (EVH) and Cormedix (CRMD)
Truist Financial Remains a Buy on Cormedix (CRMD)
Cormedix Analyst Ratings
No Data
No Data